Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine.

about

Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera.BsaXI/RFLP analysis of initial or selectively reamplified PCR product is unreliable in detecting the V617F mutation in JAK2.

P2860

Q34058657-AEF42C7F-77F2-4C7C-B113-729735629ECD Q53286392-791CE1D7-91D6-4CC5-AB11-57259E6BD8B1

P2860

Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine.

Item

http://www.wikidata.org/entity/Q39691088

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Melting point assay for the JA ...... mplications for daily routine.

@en

Melting point assay for the JA ...... mplications for daily routine.

@nl

type

Item

label

Melting point assay for the JA ...... mplications for daily routine.

@en

Melting point assay for the JA ...... mplications for daily routine.

@nl

prefLabel

Melting point assay for the JA ...... mplications for daily routine.

@en

Melting point assay for the JA ...... mplications for daily routine.

@nl

P1476

Melting point assay for the JA ...... implications for daily routine

@en

P2093

Eckhard Thiel

http://www.w3.org/2001/XMLSchema#string

P2860

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Identification of an acquired JAK2 mutation in polycythemia vera.

JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.

P2888

bf03256372

P304

185-190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/BF03256372

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sebastian Ochsenreither

Thomas Burmeister

Mark Reinwald

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20560681

http://www.w3.org/2001/XMLSchema#string

Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine.

about

P2860

P2860

Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698